Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Top Cited Papers
Open Access
- 18 March 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest cancers worldwide. Advanced HCC overall survival is meager and has not improved over the last decade despite approval of several tyrosine kinase inhibitors (TKi) for first and second-line treatments. The recent approval of immune checkpoint inhibitors (ICI) has revolutionized HCC palliative care. Unfortunately, the majority of HCC patients fail to respond to these therapies. Here, we elaborate on the immune landscapes of the normal and cirrhotic livers and of the unique HCC tumor microenvironment. We describe the molecular and immunological classifications of HCC, discuss the role of specific immune cell subsets in this cancer, with a focus on myeloid cells and pathways in anti-tumor immunity, tumor promotion and immune evasion. We also describe the challenges and opportunities of immunotherapies in HCC and discuss new avenues based on harnessing the anti-tumor activity of myeloid, NK and γδ T cells, vaccines, chimeric antigen receptors (CAR)-T or -NK cells, oncolytic viruses, and combination therapies.Keywords
Funding Information
- Fondation ARC pour la Recherche sur le Cancer
This publication has 130 references indexed in Scilit:
- Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis BProceedings of the National Academy of Sciences of the United States of America, 2012
- Expression of tumour-specific antigens underlies cancer immunoeditingNature, 2012
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinomaCancer Science, 2009
- Comprehensive analysis of the α-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinomaJournal of Hepatology, 2008
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular CarcinomaCancer Research, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinomaJournal of Hepatology, 2006
- Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular CarcinomaClinical Cancer Research, 2006
- Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular CarcinomaClinical Cancer Research, 2004